Neuracle has formally initiated its IPO course of on China’s STAR Market. In keeping with latest disclosures, the corporate signed an IPO tutoring and advisory settlement with CITIC Securities on February 4, 2026, marking the official begin of its itemizing preparations.
This makes Neuracle one of many newest mind–laptop interface (BCI) firms to maneuver towards public markets. Earlier, BrainCo—one of many so-called “Hangzhou Six Little Dragons”—confidentially filed for an IPO in Hong Kong.
Based in 2011, Neuracle’s core workforce comes from Tsinghua College’s Neural Engineering Laboratory, ranked among the many world’s prime 5 analysis establishments in mind–laptop intelligence, together with skilled professionals from the scientific neurology and medical machine sectors. The corporate focuses on proprietary mind–laptop interface applied sciences and specializes within the R&D, manufacturing, gross sales, and technical providers of BCI techniques, offering built-in options for neuroscience analysis in addition to the analysis, therapy, and rehabilitation of neurological issues.
In October 2023, Neuracle’s implantable BCI product NEO accomplished its first human implantation at Xuanwu Hospital of Capital Medical College. Subsequent feasibility research have been carried out at main medical facilities together with Beijing Tiantan Hospital, Huashan Hospital in Shanghai, and Jiangsu Provincial Individuals’s Hospital, yielding constructive outcomes. In August 2024, NEO was accepted into the Nationwide Medical Merchandise Administration’s (NMPA) Particular Evaluation Pathway for Progressive Medical Units, turning into the primary mind–laptop interface product in China to enter this channel.
Within the second half of 2025, inside a span of simply 78 days, 32 sufferers with cervical spinal wire accidents throughout 11 hospitals nationwide underwent NEO implantation procedures. No device-related antagonistic occasions have been reported post-surgery, with cumulative protected implantation time approaching 5,000 days, offering early validation of the security and long-term feasibility of the minimally invasive epidural implantation strategy.
In keeping with Neuracle Founder and Chief Engineer Honglai Xu, the model submitted for medical machine approval is NEO 1.0, whereas NEO 2.0 is beneath improvement and can add capabilities resembling speech decoding and effective motor decoding. The following-generation system targets additional enhancements in minimally invasive procedures, larger channel capability, and decrease prices, as the corporate accelerates its expertise iteration.
Since its institution, Neuracle has raised funding from a variety of institutional traders, together with Sequoia China, QF Capital, Futeng Capital, Rongtuo Capital, Pudong Science and Know-how Innovation Group, Songhe Capital, Huakong Fund, Lianxin Capital, Lizhong Funding, Zhongguancun Capital, Baidu Ventures (BV), Changzhou Authorities Funding Fund, DT Capital, and Yuan Science Enterprise Capital, amongst others.
Supply: IPOzaozhidao
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the newest breakthroughs, get unique updates, and join with a world community of future-focused thinkers.
Unlock tomorrow’s developments at this time: learn extra, subscribe to our publication, and develop into a part of the NextTech group at NextTech-news.com
